Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Peter Kolchinsky’s RA Capital Management Reported Stakes In $DYAX, $POZN, And $SQNM

Peter Kolchinsky’s RA Capital Management reported its passive stake in Dyax Corp (DYAX), Pozen Inc. /NC (POZN), and Sequenom Inc. (SQNM) on December 9th.

Peter Kolchinsky

RA Capital Management did not report any shares in DYAX and POZN in the third quarter, so these two might be new positions in RA Capital Management’s portfolio. Now RA Capital Management takes 5.29 million shares or 5.36% passive stake in DYAX, and 2.12 million shares or 7.08% passive stake in POZN.

RA Capital Management boosted its stake in SQNM to 5.20%, according to the SEC 13G. As disclosed at the end of September, RA Capital Management had 2.64 million shares in SQNM. So now the firm position is nearly doubled.

In the third quarter, three hedge funds invested in all the three stocks. They are Jim Simons’ Renaissance Technologies, David E. Shaw’s D. E. Shaw, and Israel Englander’s Millennium Management.

Peter Kolchinsky is the co-founder and general partner of RA Capital Management. He graduated from Harvard with a Ph.D. in virology in 2001. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment became $13 Million. Boston-based RA Capital invests in companies with promising drugs and technologies.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!